Stock PRAX PRAXIS PRECISION MEDICINES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Praxis Precision Medicines, Inc.

Equities

PRAX

US74006W2070

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-23 pm EDT 		5-day change 1st Jan Change
42.71 USD +0.38% Intraday chart for Praxis Precision Medicines, Inc. -2.93% +91.70%
May. 13 Praxis Precision Medicines, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 01 Baird Initiates Praxis Precision Medicines With Outperform Rating, $117 Price Target MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Encephalopathy Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)
AQ
PRAXIS PRECISION MEDICINES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
AQ
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
AQ
Praxis Precision Medicines : May 2024 Corporate Presentation
PU
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
AQ
Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024
AQ
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Praxis Precision Medicines : April 2024 Corporate Presentation
PU
PRAXIS PRECISION MEDICINES TO PRESENT ON ULIXACALTAMIDE AT THE AMERICAN ACADEMY OF NEUROLOGY 2024 ANNUAL MEETING
AQ
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
AQ
Praxis Precision Medicines to Participate in Upcoming April Conferences
AQ
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering
AQ
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
AQ
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
AQ
Praxis Precision Medicines to Host PRAX-628 Program Update
AQ
Praxis Precision Medicines : March 2024 Corporate Presentation
PU
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
AQ
Praxis Precision Medicines to Participate in TD Cowen’s 44th Annual Health Care Conference
AQ
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PRAX Stock
  4. News Praxis Precision Medicines, Inc.
  5. Press Releases